Kornimate/medical-research-clean huggingface dataset:
role of echocardiography in the assessment of right ventricular function in the pediatric population with valvular pulmonary stenosis.

Conditions: Right Ventricular Dysfunction

Summary: correct assessment of right ventricular function by transthoracic echocardiographic examination in pediatric patients with congenital valvular pulmonary stenosis after percutaneous balloon pulmonary valvuloplasty

the right ventricle plays an important role in the morbidity and mortality of patients presenting with signs and symptoms of cardiopulmonary disease. however, the systematic assessment of right heart function is not uniformly carried out. this is due partly to the enormous attention given to the evaluation of the left heart, a lack of familiarity with ultrasound techniques that can be used in imaging the right heart, and a paucity of ultrasound studies providing normal reference values of right heart size and function. in patients with chd, the right ventricle (rv) may function as either the sub-pulmonary or the systemic ventricle as in transposition of great arteries (tga). chd more commonly affecting the right heart includes atrial septal defects (asd), tetralogy of fallot (tof), pulmonary stenosis (ps), ebstein anomaly, arrhythmogenic right ventricular cardiomyopathy (arvc), and pulmonary valve atresia. in many of these patients, prevention of "irreversible" right heart failure (rhf) will require timely corrective surgery or when not possible, surgical palliation . congenital pulmonary valve stenosis is a common congenital heart disease. isolated pulmonary valve stenosis comprises 8-10% of all congenital heart disease . while surgical pulmonary valvotomy has been available as a treatment since 1956, it requires a median sternotomy, use of cardiopulmonary bypass, and post-surgical icu admission with multi-day hospitalization. recognizing the potential advantages of a less invasive approach, the first attempts at percutaneous catheter-based dilation of stenotic pulmonary valves were performed in the 1950s. as the technique was refined and catheter and balloon technology have advanced, the results of balloon pulmonary valvuloplasty have improved and the approach has become the standard of care for treating pulmonary valve stenosis

Eligibility criteria:
inclusion criteria: * all pediatric patients with congenital valvular pulmonary stenosis attending echocardiographic outpatient clinic of assuit university children hospital aged from one month to18 years old exclusion criteria: age less than one month and older than 18 years. patients with infundibular and supravalvular pulmonary stenosis
the effect of nebulization positions in asthmatic children

Conditions: Asthma Attack; Asthma in Children; Asthma Acute; Asthma

Summary: the purpose of this study was to establish the effect on pulse rate, oxygen saturation, respiratory rate, pain and anxiety levels of fowler's and the forward-leaning positions during nebulization in children experiencing asthma attacks.

in the first stage, data on the children who agreed to participate in the study were recorded on the "patient identification form" 10 minutes before the procedure by the researcher during a face-to-face interview. the children's body temperature, oxygen saturation, pulse rate and respiratory rate were measured. upon explaining the fps-r, the children were asked whether they had experienced pain before treatment, and to point at the pain level felt from among the faces on the scale. then, csa was explained and the children, and their level of anxiety on the scale was recorded. the pre-nebulization findings were recorded. in the second stage, the salbutamol therapy prescribed by the physician was administered to the participating children with a nebulizer three times at 20-minute intervals. during nebulization, the study group patients were placed in forward-leaning position, placing a pillow on their knees, while the control group was placed in fowler's position on a chair. nebulization took an average of 10 minutes for each child. oxygen saturation, pulse and respiratory rate were recorded immediately after the mask was removed. the children were allowed to rest for 20 minutes in fowler's position. in the third stage, oxygen saturation, pulse and respiratory rate were determined immediately after the mask was removed following a 10-minute second nebulization. the values determined were recorded, and the children were allowed to rest for 20 minutes in fowler's position. in the fourth stage, oxygen saturation, pulse and respiratory rate were determined immediately after the mask was removed following the 10-minute third nebulization. the children were asked whether they had pain, and to point at the pain level represented by the faces on the scale. the patients then marked their level of anxiety on the csa. the post-nebulization findings were recorded.

Eligibility criteria:
inclusion criteria: * to be between 6-11 ages, * having a body temperature below 37.2°c at admission, * having been prescribed nebulized salbutamol by the physician during data collection, * having not using bronchodilators or corticosteroid drugs within the last 6 hours, * having no other respiratory system disease, * verbal and written consent of the child and parent to participate in the study. exclusion criteria: * administering drugs other than nebulized salbutamol to the child during data collection, * having an obstacle for positioning (lordosis, kyphosis, scoliosis, chest wall deformities, previous surgical procedure, etc.), * child and parent not knowing turkish.

Keywords: asthma attack child nurse nebulization chest pain
safety and efficacy study of photodynamic therapy with levulan kerastick + blue light for actinic keratoses on the upper extremities

Conditions: Actinic Keratosis

Summary: the purpose of this study is to determine if levulan photodynamic therapy (pdt) is safe and effective in the treatment of actinic keratoses on the upper arms and hands


Eligibility criteria:
inclusion criteria: * four to fifteen grade 1/2 actinic keratosis lesions (aks) on one upper extremity exclusion criteria: * pregnancy * grade 3 and/or atypical \>1cm aks within treatment area * history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis * lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the treatment area * skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy * subject is immunosuppressed * unsuccessful outcome from previous ala-pdt therapy * currently enrolled in an investigational drug or device study * has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment * known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol) * use of the following topical preparations on the extremity to be treated: * keratolytics including urea (greater than 5%), alpha hydroxyacids \[e.g.glycolic acid, lactic acid, etc. greater than 5%\], salicylic acid (greater than 2%) within 2 days of initiation of treatment. * cryotherapy within 2 weeks of initiation of treatment * retinoids, including tazarotene, adapalene, tretinoin, within 4 weeks of initiation of treatment. * microdermabrasion, laser ablative treatments, ala-pdt, chemical peels, 5-fu, diclofenac, ingenol mebutate, imiquimod or other topical treatments for ak within 8 weeks of initiation of treatment. * use of systemic retinoid therapy within 6 months of initiation of treatment.

Keywords: actinic keratosis
pharmacokinetic study of aralast (human alpha1- pi)

Conditions: Alpha 1-Antitrypsin Deficiency

Summary: the primary purpose of this study is to characterize the pharmacokinetic profile of intravenous aralast fraction (fr.) iv-1, a sterile, stable, lyophilized preparation of functionally intact human alpha1- proteinase inhibitor (α1-pi). this pharmacokinetic study will be a randomized controlled clinical trial with a cross-over design. twenty-four subjects will be enrolled into the study. overall study duration will be approximately 6-8 months.


Eligibility criteria:
inclusion criteria: * the subject or subject´s legally authorized representative has provided written informed consent * subject is 18 years of age or older * subject has a documented, endogenous plasma alpha1-pi level \< 8 micromolar * subject is of the genotype pi\*z/z, pi\*z/null, pi\*null/null, pi\*malton/z, or others, dependent on the approval by the sponsor * if the subject is female or of childbearing potential, the subject has a negative urine test for pregnancy within 7 days prior to first study product administration and agrees to employ adequate birth control measures for the duration of the study * laboratory results obtained at the screening visit, meeting the following criteria: * serum alanine aminotransferase (alt), aspartate aminotransferase (ast) \<= 2 times the upper limit of normal (uln) * serum total bilirubin \<= 2 times uln * proteinuria \< +2 on dipstick analysis * serum creatinine \<= 1.5 times uln * absolute neutrophil count (anc) \>= 1500 cells/mm3 * hemoglobin \>= 10.0 g/dl * platelet count \>= 10\^5/mm3 * if the subject is treated with any respiratory medications, including inhaled bronchodilators and inhaled or oral corticosteroids, the subjects´ medication doses were unchanged for at least 14 days prior to first study product administration * nonsmoker for a minimum of 3 months prior to first study product administration exclusion criteria: * the subject has received any alpha1-pi augmentation therapy (including aralast and investigational alpha1-pis, by any route including intravenous and inhaled) within 42 days prior to first study product administration * the subject has received an investigational drug or device within 1 month prior to first study product administration, or the subject is currently receiving an investigational drug * the subject has a known selective immunoglobulin a (iga) deficiency (iga level \< 15 mg/dl) and/or antibody to iga * the subject has a pulmonary exacerbation or had a pulmonary exacerbation in the past 14 days prior to first study product administration * the subject is pregnant or lactating, or intends to become pregnant during the course of the study * the subject has a clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance

Keywords: severe congenital alpha1-proteinase inhibitor (alpha1-pi) deficiency
ph-797804 lps study in healthy volunteers

Conditions: Healthy

Summary: the study was performed to assess the effect of ph-797804 on neutrophils (white cells) in the sputum after a challenge with an endotoxin (inhaled lps). neutrophils are a sign of inflammation and ph-797804 is being developed as a potential anti-inflammatory treatment for patients with chronic obstructive pulmonary disease (copd).


Eligibility criteria:
inclusion criteria: * healthy male or female (woncbp), non atopic volunteers aged 18-50 years * able to produce sputum exclusion criteria: * current smokers * abnormal liver function test * respiratory tract infection within 4 weeks

Keywords: copd lps
enhancing the clinical effectiveness of depression screening using patient-targeted feedback in general practices

Conditions: Depression

Summary: the multi-center get.feedback.gp randomized controlled trial is designed based on patients' needs and preferences. in order to evaluate the effect of feedback in the broader setting of primary care, a total of 1076 primary care patients with elevated levels of depression (phq-9 score ≥ 10) will be randomized into three groups who either receive a) patient-targeted and physician-targeted feedback of depression screening results, b) a physician-targeted feedback of depression screening results only, or c) no feedback of screening results. the primary study outcome is depression severity after 6 months, secondary outcomes include the patients' behavior and cognitions after the screening, depression care according to german guideline recommendations and the health economic evaluation.

major depression is one of the most significant clinical disorders. in primary care, every sixth patient suffers from increased depression level, which is associated with higher risk of suicide, increased risk of onset and progression of chronic physical conditions. still, depression is under recognized and undertreated in primary care. moreover, evidence regarding the efficacy of depression screening in primary care is insufficient to draw clear conclusions. our previous mono-center depression screening trial in cardiac patients, provides first evidence that written patient-targeted feedback improves depression severity, encourages greater patient participation and engagement in mental health. to amplify these effects, the multi-center get.feedback.gp randomized controlled trial is now designed based on patients' needs and preferences. in order to evaluate the effect of feedback in the broader setting of primary care, a total of 1076 primary care patients with elevated levels of depression (phq-9 score ≥ 10) will be randomized into three groups who either receive a) patient-targeted and physician-targeted feedback of depression screening results, b) a physician-targeted feedback of depression screening results only, or c) no feedback of screening results. the primary study outcome is depression severity after 6 months, secondary outcomes include the patients' behavior and cognitions after the screening, depression care according to german guideline recommendations and the health economic evaluation.

Eligibility criteria:
inclusion criteria: * gender: male, female, diverse * maximum age: no maximum age * attendance in primary care with medical consultation * age ≥ 18 years; * sufficient language skills; * informed consent * patient health questionnaire-9 \> 9 points exclusion criteria: * life threatening health status; * severe somatic or/and psychological disorder that needs urgent treatment; * known diagnosis of a depressive disorder * current depression treatment * acute suicidal tendency; * severe cognitive or/and visual difficulties; * not being able to fill out questionnaires * no contact details

Keywords: depression screening primary care general practice feedback
a comparison of the alignment achieved using computer-guided indirect bonding of orthodontic brackets to conventional appliance placement

Conditions: Malocclusion

Summary: technological advances have made computer aided orthodontic treatment planning possible. 3d dental scanners and software make it possible to design and approve the outcome before treatment begins. manufacturers have provided different customized appliance systems that would help practitioners achieve those computer-designed outcomes. the purpose of this study is to determine the accuracy of computer-guided indirect bonding of orthodontic brackets at achieving the predicted alignment and comparing that to the accuracy of conventional orthodontic bracket placement at achieving a predetermined goal. the results of this study will help orthodontists and patients know if there is an advantage to using custom appliances. the study will be a prospective clinical study and will include a total of 60 arches from 30 patients enrolled at the harvard school of dental medicine. 15 patients will be assigned to each of the two study groups (motion view or control). both groups will have a 3d intra-oral scan to measure the initial discrepancy and determine the computer-simulated design that the orthodontist believes is the optimized outcome. at the end of each patient's participation, a 3d intraoral scan will be taken and used to assess intra-arch leveling and alignment using abo's objective grading system's criteria for alignment, marginal ridges and buccolingual inclination. each arch will then be superimposed on the predicted outcome to determine how accurate each system was at achieving the planned movements in all 3 dimensions. we hypothesize that the accuracy of computer-guided indirect bonding (motion view) at achieving the predicted outcomes will differ in comparison to the accuracy of conventional orthodontic bracket placement at achieving a predetermined goal.


Eligibility criteria:
inclusion criteria: * healthy subjects seeking orthodontic care * all permanent teeth must be erupted, excluding second and third molars * class i, ii, and iii cases * no more than 7 mm crowding * no more than 45 degrees of rotations exclusion criteria: * presence of systemic disease * craniofacial anomalies, including cleft lip and palate * syndromes affecting bone or teeth * congenitally missing teeth, excluding third molars * presence of bridges or implants * periodontal disease * use of drugs affecting tooth movement or bone metabolism (nsaids, bisphosphonates, pth, corticosteroids) * pregnancy

Keywords: conventional orthodontic treatment motion view
role of recombinants in peach allergy

Conditions: Food Allergy

Summary: this study is aimed at verifying the role and the efficacy of the recombinants allergens pru p 1, pru p 3 and pru p 4, bet v 1, bet v 2 and bet v 4 in the diagnosis of peach allergy

this study intend to verify whether the different levels of severity of the clinical allergic reactions to peach are associated to sensitization towards different allergenic molecules of peach. in particular, we will analyze the reactivity towards the peach allergens pru p 1, pru p 3 and pru p 4 and towards the birch pollen allergens bet v 1, bet v 2 and bet v 4. the patients (with allergic symptoms of any severity provoked by the consumption of peach) will be divided into two groups: the first group showing oral allergy syndrome (oas), the second group showing systemic symptoms of different severity, up to anaphylaxis. all the patients will be submitted to: complete clinical investigation; skin prick test with a panel of common food/inhalant commercial extracts; skin tests by the "prick + prick" method with fresh fruits and vegetables; skin prick test with purified peach ltp (pru p 3) the sera of the patients will be used for: immunoblotting with peach extract and immunoblotting inhibition with purified natural pru p 3 and, if possible, recombinant pru p 3, pru p 1 and pru p 4, using a pool of selected sera; cap system with a predetermined panel of fruit and vegetable allergens; cap system with recombinant allergens of peach and birch pollen: pru p 3, pru p 1 and pru p 4 for peach, bet v 1, bet v 2 and bet v 4 for birch pollen. finally, a statistical analysis will be carried out in order to verify if the two groups of patients will show significant differences in the allergens recognized. the results of this study will be a property of the unit of allergology and immunology as stated by dm 17/2004 and will be presented as written publication or oral presentation at national and/or international congresses of allergy and immunology, quoting the phadia company

Eligibility criteria:
inclusion criteria: * female and male; * pts with 18 e 80 years old; * signature of the informed consent form; * cap/rast positive for peach; * clinical manifestation of peach allergy exclusion criteria: * pregnancy; * current antihistamine therapy; * subjects that do not give consent to the study

Keywords: allergy, peach, birch recombinants allergens diagnosis oas ltp systemic reactions subjects with severe reaction to other fruits
intrathecal atropine to prevent postoperative nausea and vomiting

Conditions: Postoperative Nausea

Summary: optimal postoperative pain control with intrathecal morphine, with proper prevention of postoperative nausea and vomiting. dexamethasone, and or atropine could offer some protection against nausea and vomiting.

one of the gold standards for analgesia following cesarean delivery is intrathecal morphine, which is not devoid of complications namely postoperative nausea and vomiting. we evaluated the antiemetic effect of intravenous dexamethasone combined with intrathecal atropine after cesarean delivery under spinal bupivacaine plus morphine anesthesia.

Eligibility criteria:
inclusion criteria: * females * 18-40 years of age * elective cesarean delivery under bupivacaine spinal anesthesia exclusion criteria: * renal disease * preeclampsia * liver disease * cardiac disease * coagulopathy * chronic cough * nausea * vomiting * patient refusal

Keywords: postoperative nuasea
regenerative endodontic treatment of mature necrotic teeth with apical periodontitis

Conditions: Necrotic Pulp; Apical Periodontitis

Summary: the aim of this prospective, randomized, controlled double-blind study is to evaluate the effectiveness of biodentine compared with mta used as pulp space barrier on discoloration of teeth after regenerative based non-obturation root canal treatment in mature single canal with pulp necrosis and apical periodontitis.

• regenerative endodontic treatment will be performed through two visits: first visit aims to clean and disinfect the tooth canal by copious irrigation with naocl and edta solution . at the end of first visit, canal will be dressed by caoh as intracanal medicaments. second visit will be after two weeks. after removal of caoh dressing by copius irrigation, evoking bleeding inside canal by over instrumentation. when blood become semi-coagulated, according to the random sequence number of the participants, either biodentine or white mta will be placed as pulp space barrier. at the end of treatment, the access cavity will be sealed with composite restoration.

Eligibility criteria:
inclusion criteria: 1. tooth type: single-rooted teeth (anterior or premolar) encasing of one root canal with mature root (closed apex). 2. negative response of pulp tissue to electrical or thermal pulp tester. 3. widening in lamina dura or periapical radiolucency not more than 3 mm. exclusion criteria: * 1. patients having significant systemic disorder or immunocompromised patients. 2. teeth with generalized chronic periodontitis or have periodontal pocket larger than 3 mm. 3. teeth with developmental anomalies (i.e, dens invaginatusor a palatogingival groove). 4. teeth with previous root canal. 5. teeth need to post and core as final restoration

Keywords: necrotic pulp, apical periodontitis regeneration mta biodentine
radiation therapy in combination with brachytherapy for clinically localized, intermediate risk prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to test the safety and side effects "of "ultra-hypofractionated" radiation therapy when used after brachytherapy (radiation implants). this treatment delivers a higher radiation dose with each treatment over a shorter period of time.


Eligibility criteria:
inclusion criteria: * intermediate risk prostate cancer patients will be eligible for this study. intermediate risk grouping will be assessed per nccn guidelines as: * pathologically-proven diagnosis of prostate adenocarcinoma * psa 10-20ng/ml or * gleason =7 or * clinical stage t2b/c * clinical stage t2b/c additionally, patients will be required to meet the following criteria * age ≥18 * kps≥70 * prostate volume ≤ 60cc (cytoreductive androgen deprivation therapy prior to brachytherapy of ≤ 6 months duration will be allowed to achieve this goal). for patients with a prostate volume between 50-60ccs, hormone therapy will be at the discretion of the physician. * international prostate symptom score ≤15 exclusion criteria: * prior prostate surgery (including turp) * prior history of chronic prostatitis or urethral stricture * inflammatory bowel disease * prior history of pelvic radiotherapy * unable to give informed consent * metastatic disease.

Keywords: radiation therapy brachytherapy 14-163